

Research

Open Access

## Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention

Peter Emau\*, Yonghou Jiang, Michael B Agy, Baoping Tian, Girma Bekele and Che-Chung Tsai

Address: Washington National Primate Research Center, University of Washington, Box 357330 Health Sciences Building, Seattle, Washington 98195, USA

Email: Peter Emau\* - pemaub@bart.rprc.washington.edu; Yonghou Jiang - yhjiang@bart.rprc.washington.edu; Michael B Agy - magy@bart.rprc.washington.edu; Baoping Tian - baoping@bart.rprc.washington.edu; Girma Bekele - girma@bart.rprc.washington.edu; Che-Chung Tsai - ctsai@bart.rprc.washington.edu

\* Corresponding author

Published: 28 November 2006

Received: 29 August 2006

*AIDS Research and Therapy* 2006, 3:29 doi:10.1186/1742-6405-3-29

Accepted: 28 November 2006

This article is available from: <http://www.aidsrestherapy.com/content/3/1/29>

© 2006 Emau et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** A 4-week, uninterrupted treatment with 9-(2-phosphonyl-methoxypropyl)adenine (PMPA, commonly called tenofovir) completely prevents simian immunodeficiency virus (SIV<sub>mne</sub>) infection in cynomolgus macaques if treatment begins within 24 hours after SIV<sub>mne</sub> inoculation, but is less effective if treatment is delayed or duration of treatment is shortened. Critical factors for efficacy include timing and duration of treatment, potency of antiretroviral drug and a contribution from antiviral immune responses. Therefore, we evaluated the impact of one or more treatment interruptions plus SIV<sub>mne</sub> re-exposures on efficacy of PMPA treatment to prevent SIV<sub>mne</sub> infection in cynomolgus macaques. We also evaluated whether macaques with pre-existing SIV immune responses show increased efficacy of treatment. Eight PMPA-treated, virus-negative and seronegative macaques, and five PMPA-treated, virus-negative but weakly or strongly seropositive macaques were re-inoculated with SIV<sub>mne</sub> and treated with PMPA starting 24 hr post inoculation. Thereafter, they received either a 5-week treatment involving one interruption plus one SIV<sub>mne</sub> challenge or a 10-week treatment involving six interruptions plus six SIV<sub>mne</sub> challenges early during treatment. Parameters measured were plasma SIV RNA, SIV-antibody response, CD4+ T lymphocyte subsets and *in vivo* CD8+ cell-suppression of virus infection.

**Results:** All seronegative macaques developed persistent antibody response beginning 4 to 8 weeks after stopping PMPA-treatment in absence of viremia in a majority of macaques and coinciding with onset of intermittent viremia in other macaques. In contrast, all weakly or strongly seropositive macaques showed immediate increase in titers (> 1600) of SIV antibodies, even before the end of PMPA-treatment, and in absence of detectable viremia. However, *in vivo* CD8+ cell depletion revealed CD8 cell-suppression of viremia and persistence of virus in the macaques as long as 2 years after PMPA-treatment, even in aviremic macaques. Unlike untreated macaques, a treated macaque controlled viral replication and blocked CD4+ T cell depletion when challenged with a heterologous chimeric SIV/HIV-1 virus called SHIV<sub>89.6P</sub>.

**Conclusion:** A single interruption plus one SIV<sub>mne</sub> challenge was as sufficient as six interruptions plus six SIV<sub>mne</sub> challenges in reducing efficacy of PMPA, but results in long-term persistence of virus infection suppressed by CD8+ cells. Efficacy of PMPA treatment was highest in macaques with pre-existing SIV immune responses.

## Background

Despite expanding use of antiretroviral therapy (HAART) [1], which has clearly extended lives of persons infected with human immunodeficiency virus (HIV) [2,3], the virus continued to spread worldwide at nearly 5 million new infections in 2005 [4]. Therefore, there is a need to revisit proven strategies of HIV prevention with a goal to understand their limitations and maximize their effectiveness. A strategy of post exposure prophylaxis (PEP) using highly potent antiretroviral drugs is effective in preventing human immunodeficiency virus (HIV) transmission in clinical situations where treatment can be started immediately after virus exposure. For example, in preventing vertical transmission of HIV from HIV-infected mothers to their infants [5,6], following occupational exposure to HIV in blood and body fluids from HIV-infected persons [7,8] or following sexual assault or intravenous drug use [9,10]. Nevertheless, major barriers to the success of the program are uncertainty as to the time of virus exposure and poor compliance in completing treatment regimen, partly due to drug toxicity [9-11]. Therefore, a regimen of pre-exposure prophylaxis is being evaluated for preventing HIV infection in high-risk, HIV-negative persons, such as sex workers whereby highly potent antiviral drugs are taken before high-risk behavior [9,12]. The rationale for pre or post exposure prophylaxis is that after HIV exposure there is a brief window of time, before the virus spreads systemically throughout the lymphoid organs, when initiating potent antiretroviral therapy might prevent or modify viral replication. In clinical settings in which compliance to treatment is poor and a potential exist for re-exposures to virus, PEP should at least reduce virus to a level sufficient to stimulate protective immune response such as antiviral CD8+ cells and thus reduce the probability of establishing persistent, productive infection. The efficacy of such regimen depends on the timing and duration of treatment, use of highly potent antiretroviral drugs and by immune responsiveness of the host [13,14].

We showed previously that early treatment with [(R)-9-(2-phosphonylmethoxypropyl)adenine] (PMPA) can completely prevent SIV<sub>mne</sub> infection in cynomolgus macaques if treatment begins within 24 hours post-inoculation (p.i.) and is continued uninterrupted for 4 weeks, but is less effective if the initiation of treatment is delayed or if the duration of treatment was shortened [15,16]. The highest efficacy achieved required an effective regimen (i.e. 24-hour p.i., 28-day treatment) that maintained therapeutic levels of PMPA to block the spread of virus, perhaps with a contribution from antiviral immune response. The less effective regimens such as delayed initiation of PMPA treatment or shortened duration of PMPA-treatment revealed the contribution of immune response to efficacy. These regimens resulted in either delayed establishment of virus infection or induced viral control

by macaques leading to transient infections [15]. Additionally, although the PMPA-protected macaques remain free of detectable virus or SIV antibody response, they show partial resistance to challenges with homologous or heterologous SIV [17,18]. Even after the onset of SIV infection in macaques, the initiation of PMPA treatment during primary infection can induce immune suppression of SIV infection [19-23] mediated by CD8+ lymphocytes [18,24]. These studies indicated that regimens of early PEP with PMPA induce antiviral immune responses in macaques to control subsequent virus infection. The CD8+ lymphocyte-mediated control of virus replication is also a major mechanism by which early antiretroviral treatment of acute HIV-1 infection induces immune control of viral replication in HIV-1 infected persons [25]. The high potency of early PMPA treatment may be due to the rapid intracellular phosphorylation of PMPA into its active metabolites and the long half-life of these active metabolites [26], which disrupts the replication cycle of virus.


In the present study, we revisited our post exposure chemoprophylaxis against acute SIV<sub>mne</sub> infection in cynomolgus macaques [15-17] as an animal model for studying factors involved in efficacy of early antiretroviral intervention in HIV infection. We evaluated the impact of one or more interruptions of PMPA-treatment plus re-exposures to virus on the prevention of SIV<sub>mne</sub> infection and induction of CD8+ lymphocyte-mediated suppression of viremia in cynomolgus macaques. We also evaluated whether the efficacy of early PMPA treatment is greatest in macaques with pre-existing immune response to SIV.

## Results

### Efficacy of PMPA-treatment

The study subjects, called PEP-macaques, were fourteen cynomolgus macaques with a prior history of post exposure prophylaxis (PEP) of SIV<sub>mne</sub> infection using tenofovir (PMPA) or adefovir (PMEA) [15-17]. When grouped by serologic outcome at the start of the present study (after 4-5 years of follow-up study); the study subjects consisted of eight virus-negative and SIV antibody-negative (VAb-) PEP-macaques, four virus-negative but weak SIV-antibody positive (VAb±) PEP-macaques, and two virus-negative and strongly SIV antibody positive (VAb+) PEP-macaques. To facilitate comparison of data for individual macaques the history of individual macaques and their study groups are shown in Table 1. The schedule and regimens of treatment interruptions and SIV<sub>mne</sub> inoculations are shown schematically in FIG 1.

Briefly, group A were three naïve, untreated cynomolgus macaques were infection controls for SIV<sub>mne</sub> inoculum. Group B were four VAb-PEP-macaques that were given a 10-week PMPA-treatment beginning 24 hours after intra-



**Figure 1**  
**A.** A schematic drawing SIV<sub>mne</sub> inoculations and treatment regimens of different groups. Arrows show schedule of SIV<sub>mne</sub> inoculation. The solid horizontal bar indicate schedule of daily PMPA treatment (30 mg/kg, subcutaneous). AID<sub>50</sub> is 50% animal infectious dose of the SIV<sub>mne</sub> used in the studies. One AID<sub>50</sub> of the SIV<sub>mne</sub> stock was approximately 10<sup>5.0</sup> TCID<sub>50</sub> tissue culture infectious dose (TCID<sub>50</sub>) by intravenous inoculation, and 100 TCID<sub>50</sub> by intrarectal inoculation. Macaques in groups B (plus macaque 93043 in group D) received a 10-week PMPA treatment beginning 24 hours after virus inoculation, including treatment interruption plus SIV<sub>mne</sub> re-inoculation with 10 AID<sub>50</sub> SIV<sub>mne</sub> at weekly intervals during the first six weeks of treatment. Macaques in groups C and D received a 5-week PMPA treatment starting 24 hours after virus inoculation, including one treatment interruption plus SIV<sub>mne</sub> re-inoculation with 10 AID<sub>50</sub> SIV<sub>mne</sub> at week 1 of treatment. Macaque 95020 (group E) was untreated. **B.** The exact timing of events during the 72 hour interruption, including timing of SIV<sub>mne</sub> re-inoculation during the treatment interruption. Treatment was initiated 24 hours after SIV<sub>mne</sub> inoculation, then continued for 5 days. Thereafter, treatment was withheld for 72 hours, during which macaques were re-inoculated with SIV<sub>mne</sub> at 48 h and re-started on treatment at 72 h. After the last inoculation, treatment was continued uninterrupted for 28 days. Note that the during the treatment interruption, the 48-hour interval between the end of treatment and SIV<sub>mne</sub> re-inoculation was approximately one half-life of PMPA active metabolites in resting lymphocytes or three times the half-life in activated lymphocytes [26].

venous SIV<sub>mne</sub> inoculation, including treatment interruption and SIV<sub>mne</sub> challenge at weekly intervals during the first six weeks of treatment. Group C were four V-Ab<sup>-</sup> PEP macaques that were given a 5-week PMPA-treatment beginning 24 hours after intravenous SIV<sub>mne</sub> inoculation, including one treatment interruption plus SIV<sub>mne</sub> challenge at week 1 of treatment. Group D was one V-Ab<sup>+</sup> -PEP

macaque that received a treatment regimen similar to group B and three V-Ab<sup>+</sup> and one V-Ab<sup>+</sup> -PEP macaques that received a regimen similar to group C. Group E was one untreated V-Ab<sup>+</sup> -PEP macaque used for SHIV<sub>89.6P</sub> challenge to compare the level of viral control in treated and untreated PEP-macaques. Virus infection in all macaques was evaluated using levels of plasma SIV RNA,

**Table 1: Macaque history and regimen of post exposure prophylaxis.**

Group	Macaque	Treatment regimens		
		Uninterrupted PEP <sup>1</sup>	Outcome after 4–5 years. <sup>2</sup>	Second PEP regimen <sup>3</sup>
A	98021	Naïve	V·Ab <sup>-</sup>	Untreated
	98034	Naïve	V·Ab <sup>-</sup>	Untreated
	98035	Naïve	V·Ab <sup>-</sup>	Untreated
B	93192	24 h pi 28 d	V·Ab <sup>-</sup> (5)	10 wk, 6 ti
	93208	24 h pi 28 d	V·Ab <sup>-</sup> (5)	10 wk, 6 ti
	95025	24 h pi 28 d	V·Ab <sup>-</sup> (4)	10 wk, 6 ti
	95044	24 h pi 28 d	V·Ab <sup>-</sup> (4)	10 wk, 6 ti
C	93194	-48 h pi 28 d	V·Ab <sup>-</sup> (5)	5 wk, 1 ti
	95054	24 h pi 28 d	V·Ab <sup>-</sup> (4)	5 wk, 1 ti
	93217	24 h pi 28 d	V·Ab <sup>-</sup> (5)	5 wk, 1 ti
	93193	4 h pi 28 d	V·Ab <sup>-</sup> (5)	5 wk, 1 ti
D	M94312	24 h pi 28 d	V·Ab <sup>±</sup> (4)	5 wk, 1 ti
	M95033	72 h pi 28 d	V·Ab <sup>±</sup> (4)	5 wk, 1 ti
	95053	24 h pi 10 d	V·Ab <sup>±</sup> (4)	5 wk, 1 ti
	93040	-48 h pi, 28 d +SIV challenge	V·Ab <sup>+</sup> (5)	5 wk, 1 ti
	93043	-48 h pi, 28 d +SIV challenge	V·Ab <sup>+</sup> (5)	10 wk, 6 ti
E	95020	24 h pi 10 d	V·Ab <sup>±</sup> (4)	NONE

All macaques in this study were cynomolgus macaques (*Macaca fascicularis*).

<sup>1</sup>PEP, post-exposure chemoprophylaxis; uninterrupted PEP (1<sup>st</sup> PEP) was performed using SIV<sub>mne</sub> infection and PMPA or PMEAs as described in studies already published [15-17] 4–5 years prior to the present study (2<sup>nd</sup> PEP). The uninterrupted PEP regimen such as 24 h pi 28 d indicates 24 hours post inoculation and 28 days of treatment.

<sup>2</sup>V·Ab<sup>-</sup> indicates virus-negative and antibody-negative; V·Ab<sup>±</sup> indicates virus-negative and weakly seropositive; V·Ab<sup>+</sup> indicates virus-negative and strongly seropositive. The numbers in brackets refers to years after uninterrupted PEP for follow-up of each macaque. Macaques 93040 and 93043 had been challenged with SIV<sub>smmpBj14</sub> at 12 months after uninterrupted PEP as described previously [17] prior to being used in the present study.

<sup>3</sup>For second PEP regimen, all previously SIV-exposed and PMPA-treated macaques were divided into groups (B – E) based in the pre-existing SIV-antibody response. Group A were three naïve macaques that served as infection controls for SIV<sub>mne</sub> virus stock. Macaques in group B and one macaque (93043) in group D were given a 10-week (10 wk) PMPA treatment that included weekly treatment interruption(t<sub>i</sub>) plus SIV<sub>mne</sub> challenge for the first six weeks of treatment (i.e. 10 wk, 6 t<sub>i</sub>). Macaques in groups C and D were given a 5-week (5 wk) PMPA treatment that included a single treatment interruption (t<sub>i</sub>) plus SIV<sub>mne</sub> challenge during the first week of treatment (i.e. 5 wk, 1 t<sub>i</sub>). Macaque 95020 in group E received uninterrupted PMPA PEP but not the second PMPA PEP and remained virus-negative and weakly seropositive throughout the follow-up studies.


SIV antibody responses and changes in lymphocyte subsets.

All three naïve, untreated macaques (group A) developed persistently high levels of plasma viral RNA within week 1 after SIV<sub>mne</sub> inoculation and titers of SIV antibodies by week 4, although the antibody response was lower in one macaque (macaque 98034) than in the other two untreated macaques (Fig. 2 and 3, group A).

When four V·Ab<sup>-</sup> PEP macaques (group B) received a 10-week PMPA treatment starting 24 hours after SIV<sub>mne</sub> inoculation, including treatment interruptions plus SIV<sub>mne</sub> challenges at weekly intervals during the first six weeks of treatment, two macaques remained viremia-negative while two developed intermittent levels of plasma viral RNA beginning 2 – 8 weeks after stopping PMPA treat-

ment. However, all the four V·Ab<sup>-</sup> PEP macaques developed persistently high titers of SIV antibodies in plasma beginning 4–8 weeks after stopping PMPA treatment (Fig. 2 and 3, group B)

Similarly, when four V·Ab<sup>-</sup> PEP macaques (group C) received a 5-week PMPA treatment starting 24 hours after SIV<sub>mne</sub> inoculation, including treatment interruption plus SIV<sub>mne</sub> challenge only at week 1 (i.e. after a 5-day treatment) of treatment, three macaques remained viremia-negative but one developed intermittent levels of plasma viral RNA beginning 3 weeks after stopping PMPA treatment. However, all the four V·Ab<sup>-</sup> PEP macaques developed persistently high titers of SIV antibodies by 4 weeks after stopping PMPA treatment (Fig. 2 and 3, group C).




**Figure 2**  
 Plasma viral load levels in untreated and PMPA-treated macaques after intravenous inoculation with uncloned SIV<sub>mne</sub>. Group A were naïve untreated macaques. Macaques in group B (plus macaque 93043 in group D) received a 10-week PMPA treatment beginning 24 hours after virus inoculation, including treatment interruption plus SIV<sub>mne</sub> re-inoculation at weekly intervals during the first six weeks of treatment. Macaques in groups C and D received a 5-week PMPA treatment starting 24 hours after virus inoculation, including one treatment interruption plus SIV<sub>mne</sub> re-inoculation at week 1 of treatment. SIV RNA in plasma measurements were performed at Bayer Diagnostics (Berkeley, CA) using a branched DNA (bDNA) signal amplification assay for SIV. This bDNA assay has a lower-limit of detection of 125 RNA copies/ml.

In contrast, when three V-Ab<sup>+</sup> PEP macaques and two V-Ab<sup>-</sup> PEP macaques (group D) received a 10-week or 5-week PMPA treatment regimen similar to that for group B or C, all five macaques remained viremia-negative throughout the 26-weeks of follow-up. Moreover, they all showed immediate increase in titers of SIV antibodies plasma within 2 weeks after the initial SIV inoculation, even before PMPA treatment ended (Fig. 2 and 3, group D).

**Analysis of lymphocyte subsets**

To determine whether the PMPA treatment also protected or improved the levels of CD4<sup>+</sup> lymphocytes in peripheral blood, the absolute numbers of CD4<sup>+</sup> lymphocytes and ratios of CD4:CD8 were analyzed for the different groups. The three naïve, untreated macaques showed a gradual decrease in CD4<sup>+</sup> lymphocytes from 2379 ± 289/uL blood (0.987 ± 0.297 CD4:CD8 ratio) before SIV inoculation to



**Figure 3**

Anti-SIV IgG antibody response in untreated and PMPA-treated macaques after intravenous inoculation with uncloned SIV<sub>mne</sub>. Group A were naïve untreated macaques. Macaques in group B (plus macaque 93043 in group D) received a 10-week PMPA treatment beginning 24 hours after virus inoculation, including treatment interruption plus SIV<sub>mne</sub> re-inoculation at weekly intervals during the first six weeks of treatment. Macaques in groups C and D received a 5-week PMPA treatment starting 24 hours after virus inoculation, including one treatment interruption plus SIV<sub>mne</sub> re-inoculation at week 1 of treatment. Titers are expressed as the reciprocal of the highest dilution that was positive by HIV-2 EIA (Sanofi-Pasteur, Redmond, WA). The lowest plasma dilution used was 1:40.

1240 ± 850/uL blood (0.835 ± 0.171 CD4:CD8 ratio) by 20 weeks of p.i.

The four V-Ab<sup>-</sup> PEP macaques (group B) that received weekly treatment interruptions plus SIV<sub>mne</sub> challenges during the first six weeks of a 10-week PMPA treatment showed no change in the CD4+ T cells from 1648 ± 527/uL blood (CD4:CD8 ratio of 1.278 ± 0.349) before treatment to 1608 ± 969/uL blood (CD4:CD8 ratio of 1.162 ± 0.298) by 20 weeks p.i. However, the four V-Ab<sup>-</sup> PEP

macaques (group C) that received treatment interruption plus SIV<sub>mne</sub> challenge only at week 1 of a 5-week PMPA treatment showed gradual increase in CD4+ lymphocytes from 1589 ± 474/uL blood (CD4:CD8 ratio of 0.887 ± 0.270) before treatment to 2037 ± 408/uL blood (CD4:CD8 ratio of 1.047 ± 0.528) by 20 weeks p.i. Similarly, the five V-Ab<sup>±</sup> or V-Ab<sup>+</sup> PEP macaques (group D) that received regimen similar to that for group B or C had gradual increase in CD4+ lymphocytes from 1523 ± 503/uL blood (CD4:CD8 ratio of 1.041 ± 0.371) before treatment

to  $1849 \pm 753/\mu\text{L}$  blood (CD4:CD8 ratio of  $1.087 \pm 0.347$ ) by 20 weeks p.i.

#### **CD8+ lymphocyte-suppression of viremia**

Control of viremia by CD8 T-cells has been found to be one of the major mechanisms for antiretroviral-induced host control of viral replication [18,24,25]. Therefore, depletion of CD8+ lymphocytes at several years after PMPA treatment T-cells would show both the induction and persistence of immune control of infection in the PEP macaques. Therefore, to demonstrate the presence and persistence of CD8+ lymphocyte-suppression of virus in PEP macaques, we performed *in vivo* CD8-cell depletion at 2 years after PMPA-treatment of four macaques (Fig.4). Two macaques (93194, 93217) were from group C and two (93040, 93043) were from group D. Of these four macaques, only macaque 93217 had developed detectable levels of plasma viremia before CD8-depletion. All other three macaques had no detectable plasma viremia prior to CD8-depletion. We used monoclonal antibody that depletes CD8+ T cells; including CD8+ natural killer (NK) cells [27]. After the onset of CD8+-depletion all the four macaques developed a rapid increase followed by decrease in levels of plasma viral RNA (Fig.3). Plasma viremia increased and then decreased to undetectable levels inversely with the levels of CD8+ lymphocytes-cells in peripheral blood. Moreover, the depletion of CD8+ lymphocyte-cells *in vivo* produced viremia in all macaques including those macaques that had remained negative for plasma viremia throughout the 2 years of follow-up.

#### **Comparison of SHIV<sub>89,6P</sub> challenge in treated and untreated PEP macaques**

Since all the study subjects had a history PMPA PEP, one question was what the effect of pre-existing immunity alone was without the second PMPA PEP regimen. To investigate this question, we compared viral control after a pathogenic, heterologous viral challenge with SHIV<sub>89,6P</sub> in two PEP-macaques that were virus-negative and very weakly SIV-antibody positive after the first PMPA PEP [15], but one (M94312, group D) that received second PEP regimen and one (macaque 95020, group E) that did not. The SHIV<sub>89,6P</sub> – obtained originally from Dr. K.A. Riemann () – is a chimeric virus of SIV/HIV-1 containing *env* gene of HIV-1<sub>89,6P</sub> on SIVmac239 backbone which causes high viral loads and a rapid decline in CD4+ T-cell levels in rhesus macaques [28] and cynomolgus macaques [29]. After receiving second PMPA PEP, macaque M94312 fully seroconverted and became persistently virus-negative with high level of SIV antibodies, whereas Macaque 95020 remained persistently virus-negative and weakly SIV antibody positive. Both macaques were challenged intravenously with 10 AID<sub>50</sub> SHIV<sub>89,6P</sub> virus (6.5 years after first PMPA PEP or 2.5 years after second PMPA PEP).

Two naïve macaques (macaques 99111 and 99107) served as infection controls for the SHIV<sub>89,6P</sub> inoculums.


The two-naïve macaques developed high levels of plasma SIV RNA that reached maximum (7,705,800 – 22,340,000 copies/mL) by week 2 after SHIV<sub>89,6P</sub> inoculation and remained persistent throughout the first 8 weeks of infection (Fig 5). Both macaques also developed a rapid decrease in peripheral blood levels of CD4+ T cells from an average of  $914 \pm 121$  cells/ $\mu\text{L}$  (CD4:CD8 ratio of  $0.715 + 0.2$ ) before inoculation to persistently low levels of 75 – 150 cells/ $\mu\text{L}$  (CD4:CD8 ratio of  $0.01 - 0.09$ ) blood during primary infection (Fig 6). These macaques developed SIV antibody response that was detectable by HIV-2 ELISA beginning week 4 post inoculation (Fig 5).

Similarly, macaque 95020 developed high levels of plasma SIV RNA that reached a maximum of 4,067,900 copies/mL week 1 post challenge and remained persistent throughout primary infection (Fig 5). Plasma viremia was accompanied by a rapid decrease in peripheral blood levels of CD4+ T cells from 931 cells/ $\mu\text{L}$  (CD4:CD8 ratio of 1.016) before challenge to a persistent low levels of 220–260 cells/ $\mu\text{L}$  (CD4:CD8 ratio of 0.15–0.2) by week 2 post challenge (Fig 6). This macaque also became fully seroconverted with high titers of SIV antibody response detectable by HIV-2 ELISA within 4 weeks post challenge. When compared with the two naïve macaques, macaque 95020 had slightly low peak plasma viremia (4,067,900 versus 7,705,800 – 22,340,000 copies/mL) and less decline in levels of CD4+ T cells (220–260 versus 75 – 150 CD4+ T cells/ $\mu\text{L}$ ).

In contrast, challenge of macaque M94312 with SHIV<sub>89,6P</sub> resulted in transient plasma viremia that reached maximum 206,577 copies/mL at week 1 post challenge and was undetectable by week 4 post challenge (Fig 5). In addition, macaque M94312 showed no depletion of CD4+ T cells in peripheral blood; instead the CD4+ T cells increased slightly from 773 cells/ $\mu\text{L}$  (CD4:CD8 ratio of 1.098) at pre-challenge to 1045–1108 cells/ $\mu\text{L}$  (CD4:CD8 ratio of 0.961 – 1.164) between weeks 4–8 after challenge(Fig 6). This macaque also showed a transient increase in titers of SIV antibodies between weeks 2 – 6 post challenge. Thus, unlike macaque 95020 and the 2 naïve macaques, macaque M94312 controlled of SHIV<sub>89,6P</sub> replication within 4 weeks after inoculation and it completely blocked the depletion of CD4+ T cells from peripheral blood.


#### **Discussion**

A 4-week, uninterrupted treatment using PMPA can completely block SIV from establishing infection in macaques if treatment is started within 24 hours after intravenous SIV inoculation, but is less effective if the initiation of




**Figure 4**  
 Relationship between levels of CD8+ cells in peripheral blood and plasma viral load in macaques during in vivo depletion of CD8+ lymphocytes. Depletion of CD8+ lymphocytes was achieved by using the monoclonal anti-CD8 antibody (cMT807) as described in the text. Depletion studies were performed 2.3 years after the end of PMPA-treatment. Levels of CD8+ lymphocytes were measured by flow cytometry and plasma viral load was quantitated by a branched DNA (bDNA) signal amplification assay for SIV as described in the text. Macaque 93217 and 93194 were from group C. Macaque 93040 and 93043 were from group D.

treatment is delayed or if the duration of treatment is shortened [15,16]. In the present study, we show that even when treatment begins 24 h p.i. a single interruption and virus challenge was as sufficient as multiple interruptions plus viral challenges in reducing the efficacy of PMPA, instead results in persistent SIV antibody responses and long-term CD8-cell mediated suppression of virus infection. The highest efficacy showed by a 4-week, uninterrupted treatment regimen was most probably due to maintenance of effective therapeutic level of PMPA necessary to allow the infected cells initiated within 24 hours of intravenous inoculation to decay completely without spreading virus infection. However, the reduced efficacy showed by interruption of treatment plus virus challenge



**Figure 5**  
 Plasma viral load (A) and SIV antibody response (B) in naive and PEP-macaques inoculated intravenously with 10 AID<sub>50</sub> chimeric SIV/HIV-1 called SHIV<sub>89,6P</sub>. PEP, post exposure prophylaxis. Macaques 95020 and M94312 were persistently virus-negative and weakly SIV-antibody positive (V-Ab<sup>±</sup>) after the first SIV<sub>mne</sub> infection/PMPA PEP regimen (1<sup>st</sup> PEP) [15]. Four years later, macaque M94312 received a second PEP regimen (2<sup>nd</sup> PEP) involving one treatment interruption plus SIV<sub>mne</sub> challenge at week 1 of a 5-week PMPA treatment. Thereafter, this macaque became persistently virus-negative and strongly-SIV antibody positive (V-Ab<sup>+</sup>). Macaque 95020 was not given a second PEP and remained persistently virus-negative and weakly-antibody positive (V-Ab<sup>±</sup>). Both macaques were then challenged with SHIV<sub>89,6P</sub> at the same time at 2.5 years after the 2<sup>nd</sup> PEP (i.e. 6.5 years after the 1<sup>st</sup> PEP). Two naive macaques (99111 and 99107) served as infection controls. Plasma viremia was quantified by a branched DNA (bDNA) signal amplification assay for SIV by Bayer Diagnostics (Berkeley, CA). The target probes for the assay are designed to hybridize with the *pol* region of SIVmac strains of virus. This assay has a lower limit of detection of 125 RNA copies/mL. Titers of SIV antibodies are expressed as the reciprocal of the highest dilution of plasma that was positive by HIV-2 EIA (Sanofi-Pasteur, Redmond, WA). The lowest plasma dilution used was 1:20.





**Figure 6**  
 Lymphocyte subsets in naive and PEP-macaques inoculated intravenously with 10 AID<sub>50</sub> chimeric SIV/HIV-1 called SHIV<sub>89.6P</sub>. Figure 1 shows absolute numbers of CD4 T cells. Figure 1B shows CD4:CD8 ratio. PEP, post exposure prophylaxis. Macaques 95020 and M94312 were persistently virus-negative and weakly SIV-antibody positive (V-Ab<sup>±</sup>) after the first SIV<sub>mne</sub> infection/PMPA PEP regimen (1<sup>st</sup> PEP) [15]. Four years later, macaque M94312 received a second PEP regimen (2<sup>nd</sup> PEP) involving one treatment interruption plus SIV<sub>mne</sub> challenge at week 1 of a 5-week PMPA treatment. Thereafter, this macaque became persistently virus-negative and strongly-SIV antibody positive (V-Ab<sup>+</sup>). Macaque 95020 was not given a second PEP and remained persistently virus-negative and weakly-antibody positive (V-Ab<sup>±</sup>). Both macaques were then challenged with SHIV<sub>89.6P</sub> at the same time at 2.5 years after the 2<sup>nd</sup> PEP (i.e. 6.5 years after the 1<sup>st</sup> PEP). Two naive macaques (99111 and 99107) served as infection controls. Lymphocyte subsets are analyzed in peripheral blood by FACSscan for absolute number of CD4+CD3+ T lymphocytes and CD8+CD3+ T lymphocytes and used to calculate the ratio of CD4:CD8 T lymphocytes in peripheral blood.

was most likely due to decreased PMPA levels, which allowed transient infections to occur, thereby re-setting decay of infected cells. As a result the level of SIV infection in macaques was not sufficient to establish full infection but was sufficient to induce persistent SIV antibody responses and CD8 cell-mediated suppression of virus infection. In the present study, the first interruption of treatment occurred after a 5-day treatment from the time of SIV<sub>mne</sub> inoculation and lasted 3 days during which macaques were re-inoculated with SIV<sub>mne</sub>. It is possible that, for the virus-negative and antibody negative macaques (V-Ab-PEP macaques in groups B and C, if treatment was interrupted later (e.g. on day 20 of treatment) during the 28-day treatment or if the interruption lasted less than three days (e.g. 1–2 days), the efficacy of PMPA would have been preserved due to the long intracellular half-life of the active metabolites of PMPA [26].

The findings that a majority of previously seronegative macaques developed SIV antibodies 4–8 weeks after treatment in the absence of detectable viremia or after transient viremia indicated that these macaques developed control of SIV replication by the time treatment was withdrawn, consistent with previous studies [19–23]. In addition, the findings that all the previously, weakly and strongly seropositive macaques (V-Ab<sup>±</sup> PEP macaques) developed high titers of SIV antibodies within 2 weeks of SIV inoculation, even before the end of treatment and in complete absence of detectable viremia, indicated immune memory response [30] to SIV in these macaques. Therefore, these results indicate that the efficacy of post exposure prophylaxis with PMPA can be significantly augmented by the pre-existing immune responses to SIV. This finding is consistent with that of other investigators that showed that the efficacy of PMPA against acute or chronic SIV infection in macaques is enhanced by the presence of CD8+ T-cells [24]. PMPA itself can stimulate lymphocytes or macrophages to secrete cytokines such as tumor necrosis factor (TNF) or chemokines such as RANTES [31,32], which may have also contributed to the efficacy of PMPA.

Unlike PMPA, other antiretroviral agents such as AZT or PMEA when given in post exposure regimen are incompletely effective in blocking acute SIV infection in macaques [33–35]. The high potency of PMPA may be attributable to its rapid intracellular phosphorylation to form active metabolites, the long intracellular half-life of these active metabolites [26] and perhaps a capacity of PMPA to activate immune cells such as monocytes or lymphocytes to secrete cytokines and chemokines [31,32]. Therefore, efficacy of post exposure prophylaxis for HIV infection may depend critically not only on the timing of initiation and duration of treatment, but also on the pharmacological properties of specific antiretroviral agents used. Good candidates include highly potent antiretrovi-

ral agents such as PMPA, which are easily activated *in vivo*, have long intracellular half-life of active drug, could activate immune system and have good safety profile.

Induction of CD8 cell-suppression of viremia is one of the mechanisms by which antiretroviral treatment, including PMPA, induces host control of virus infection [13,18,24,25]. We previously demonstrated that PEP macaques exhibit considerable CD8+ lymphocyte suppression of SIV<sub>mne</sub> *in vitro* even at CD8:CD4 ratios of 1:2 and mild suppression at ratios 1:10 [17]. Our studies show that interrupted PMPA treatment resulted in CD8+ cell-suppression of viremia that persisted for more than 2 years, even in macaques that showed no evidence of viremia. (Whether macaques previously had intermittent viremia or no detectable viremia, the results were the same: plasma viral RNA increased and then decreased to undetectable levels inversely with the levels of CD8+ lymphocytes in peripheral blood). These results demonstrate the persistence of CD8+T-cell suppression of virus infection. At the same time these results demonstrate the long-term persistence of virus in the macaques, ready to replicate immediately after removal of CD8+ T cells even in macaques without any detectable virus. Such a persistence of virus in macaque may itself be a stimulant maintaining CD8 T-cell suppression of virus replication in the macaques. These results are consistent with those of other investigators showing persistence of vaccine virus as the immune correlate of protection against late onset of AIDS in macaques [36].

A previous study showed that when a 28-day PMPA PEP regimen is used against SIV<sub>smE660</sub> infection in rhesus macaques, it can induce CD8+ cell-mediated control of viral replication and resistance to homologous challenge or heterologous challenge with SIV<sub>mac39</sub> [18]. However, a similar regimen fails if SIV<sub>mac239</sub> is used as the infecting virus in PMPA PEP [37]. Thus, the results of PMPA PEP using SIV<sub>mne</sub> in cynomolgus macaques in the present study may not apply necessarily to other SIV isolates or other species of macaques, or to antiretroviral regimens such as pre-exposure prophylaxis that completely block virus infection without inducing CD8+ immune responses. However, the results in the present study were obtained using SIV<sub>mne</sub> infection in cynomolgus macaques under specified conditions in which (i) PMPA treatment is started 24 hours after SIV<sub>mne</sub> inoculation, (ii) the first treatment interruption plus SIV<sub>mne</sub> challenge was started after a 5-day treatment, (iii) each treatment interruption lasted 3 days and macaques were challenged with SIV<sub>mne</sub> on the second day of interruption, and (iv) treatment was continued for at least 28 days after the last SIV<sub>mne</sub> challenge.

One question was how much the preexisting immunity contributed to the viral control in the PEP-macaques in the present study. This question was addressed by comparing the outcome of SHIV<sub>89.6P</sub> challenge in two PEP-macaques (95020 and M94312) that had similar outcomes from first PMPA PEP, but one macaque M94312 that received second PMPA PEP regimen whereas one (macaque 95020) did not. After the initial PMPA PEP both macaques had no detectable viremia, but they had very weak SIV-specific antibody response. Four years later, macaque M94312 was given second PEP regimen and thereafter became persistently virus-negative but strongly positive for SIV antibody response. When challenged intravenously with 10 AID<sub>50</sub> SHIV<sub>89.6P</sub>, macaque 95020 failed to control active viral replication and depletion of CD4+ T cells throughout the course of primary infection. In contrast, macaque M94312 completely controlled viral replication within 4 weeks of inoculation and completely blocked the depletion of CD4+ T cells. Although the number of macaques in this challenge study was small, the marked viral control by M94312 in contrast to macaque 95020 was most probably a contribution of second PMPA PEP regimen. It is conceivable that the individual PEP-macaques or macaque groups such as V-Ab<sup>-</sup>, V-Ab<sup>±</sup> or V-Ab<sup>+</sup> had different levels of pre-existing SIV specific CD8+ cell responses which contributed to the protection of macaques independent of PMPA. Van Rompay et al [24] demonstrated that CD8+ T cells enhanced the efficacy of PMPA treatment in controlling SIV infection. Therefore, in the presence of PMPA treatment, preexisting immune response might interact additively with PMPA to control infection. The outcome would depend on the level of pre-existing immunity [14]. Although our study has a limitation in its capacity to establish the absolute contribution in each macaque group, it provides an insight into relative contribution to efficacy by comparing the results of efficacy between macaque groups. For example, our findings show that all the seronegative (V-Ab<sup>-</sup>) PEP macaques in groups B and C seroconverted only when PMPA treatment had stopped for at least 4 – 8 weeks, irrespective of 5-week or 10-week duration of treatment. Similarly, the onset of transient or intermittent viremia in the three macaques in those groups also developed 2 – 8 weeks after stopping PMPA treatment. In contrast the macaques in group D that received a similar treatment regimen, but which were previously weakly seropositive, became fully seroconverted within two weeks of SIV inoculation, even before the end of PMPA treatment. These findings suggest strongly that, viral control was more dependent on PMPA treatment in the previously seronegative PEP macaques than in the previously weakly or strongly seropositive PEP macaques.

Overall, our studies confirm that early initiation of potent antiretroviral treatment and strict compliance to the dura-

tion of treatment are critical factors for the success of post exposure prophylaxis. The initiation of PMPA treatment during chronic SIV infection fails to control the rebound of viremia after treatment is withdrawn [38]. However, the initiation of PMPA treatment between 2 days to 6 weeks after SIV inoculation (i.e. during the primary phase of acute SIV infection) results in partial immune control of SIV rebound [19-23]. Yet, for a preventive treatment against HIV to be effective, the treatment must block the HIV from ever establishing systemic infection in the lymphoid organs [39]. We have found that the most effective regimen for blocking SIV infection in macaques is a 4-week, uninterrupted treatment using PMPA beginning before or within 24 hours of SIV intravenous inoculation [15,16]. Our study shows that if the PMPA treatment is interrupted and macaques are re-exposed to virus, then the complete protection from SIV infection is abrogated. Despite the lack of complete protection, a majority of macaques still benefit by developing long-term immune control of virus infection. More over the use of structured treatment interruptions of highly active antiretroviral therapy in HIV-infected persons [13,25] or in SIV-infected macaques [22] has been shown to induce the immune control virus infection. The effectiveness of such regimens depends on early initiation of treatment, the potency of the antiretroviral drug, and the immune responsiveness of the host [14]. In addition, a recent clinical trial in human found that under controlled conditions of CD4-guided treatment, scheduled treatment interruptions may also be beneficial in reducing the total amount of antiretroviral drug used, and thus reduce cost as well as prevent drug toxicity without the risk of developing drug resistance and loss of efficacy of treatment [40]

## Conclusion

In order for the regimen of post exposure prophylaxis to be effective in preventing HIV transmission in persons exposed to HIV in blood or body fluids from HIV-infected persons, the exposed individuals need to comply with the prescribed regimen of potent antiretroviral treatment started as early as possible. However, in cases of noncompliance to treatment regimen, our study shows that there is still a benefit to completing treatment because interrupted regimens can reduce the possibility of an established persistent viral replication and instead modifies the kinetics of viral replication to induce immune control of the infection. Our study also implies that post-exposure regimens of PMPA treatment in the SIV/macaque is a useful animal model for inducing long-term immune control of virus replication and thus useful for investigating the nature of protective immune responses and strategies of therapeutic vaccination or immune boosting against HIV.

## Materials and methods

### Macaques

The study subjects, henceforth called post-exposure prophylaxis (PEP) macaques, were fourteen *Cynomolgus* macaques (*Macaca fascicularis*) that had been previously inoculated intravenously with SIV<sub>mne</sub>, then treated with PMPA or PMEA [15-17] and evaluated for 4 to 5 years (Table 1). Three naïve macaques served as controls for infectivity of SIV<sub>mne</sub> (group A). Eight of the PEP-macaques, called V·Ab<sup>-</sup> PEP-macaques (groups B and C), were completely protected from infection since they had no detectable virus or SIV antibodies throughout the 4 – 5 years of follow-up. Four PEP-macaques (three are in group D and one is in group E), called V·Ab<sup>±</sup> PEP-macaques, had transient infection early after treatment and thereafter were free of virus but developed weak SIV antibody response (ELISA titers less than 1:200, and 1–2 bands on SIV immunoblot). Two PEP-macaques, called V·Ab<sup>+</sup> PEP-macaques (in group D), had been completely protected by treatment but when challenged with a highly pathogenic, heterologous virus (SIV<sub>smmPBj14</sub>), they resisted the challenge and became persistently positive for SIV antibodies [17]. Care and husbandry of all macaques were in strict conformance with federal guidelines. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Washington.

### Virus inoculum

The SIV<sub>mne</sub> stock used in the second PMPA PEP regimens was derived from the supernatant of uncloned SIV<sub>mne</sub> propagated in HuT 78 cells and expanded in macaque PBMCs [15,16]. One milliliter of the stock contained 10,000 viral particles of 50% tissue culture infectious doses (TCID<sub>50</sub>) as determined in human T-cell lines or 1,000 50% animal infectious doses (AID<sub>50</sub>) as determined by intravenous inoculation of macaques, or 100 AID<sub>50</sub> as determined by intrarectal inoculation of macaques. The SHIV<sub>89,6p</sub> stock used in the post PEP challenge was originally obtained from Dr. K. A. Reimann (Beth Israel Hospital, Boston MA, Reimann et al 1996) and propagated in phytohemagglutinin-A-stimulated PBMCs from naïve pigtailed macaques [40]. One milliliter of the stock contained 10,000 TCID<sub>50</sub> as determined in MT-2 cells or 1,000 AID<sub>50</sub> by intravenous inoculation in macaques.

### Regimen of post-exposure prophylaxis

The PMPA PEP regimen used in this study is illustrated schematically in Figure 1, to show the schedule of SIV<sub>mne</sub> inoculations and treatment interruptions for different groups. Three naïve macaques were used as untreated control (group A). Fourteen PEP macaques were divided into groups based on the level of their pre-existing SIV antibody response. The eight V·Ab<sup>-</sup> PEP-macaques were divided into two groups (B and C) of four macaques each. Three V·Ab<sup>±</sup> PEP-macaques and two V·Ab<sup>+</sup> PEP-macaques

formed group D. One VAb<sup>±</sup> PEP-macaque (95020) formed group E. All the macaques in groups A – D were first inoculated intravenously with 1AID<sub>50</sub> (10 TCID<sub>50</sub>) of SIV<sub>mne</sub> on day 0 and then re-inoculated intravenously 7 days later with 10 AID<sub>50</sub> (100 TCID<sub>50</sub>) SIV<sub>mne</sub>. All PEP-macaques in groups B to D were started on PMPA treatment (30 mg/kg per day, subcutaneously) beginning 24 hours after initial intravenous SIV inoculation. After 5 days of daily dosing, treatment was interrupted for 72 hours while macaques were re-inoculated intravenously with 10 AID<sub>50</sub> SIV<sub>mne</sub>. Then daily dosing resumed 24 hours after re-inoculation for additional 28 days. However, all macaques in group B and one macaque (93043) in group D received additional interruptions of PMPA-treatment plus re-challenge with SIV<sub>mne</sub> for six weeks. For these macaques, treatment was interrupted for 72 hours while macaques were re-inoculated intrarectally with 10 AID<sub>50</sub> (1, 000 TCID<sub>50</sub>) SIV<sub>mne</sub> at weekly intervals until week 6 after initial SIV<sub>mne</sub> inoculation. Thereafter, they all resumed daily dosing for additional 28 days.

#### **Depletion of CD8+ T cells in vivo**

cM-T807 anti-CD8 monoclonal antibody was received from Maine Biotechnology Services (Portland, ME 04103) and Covance Research Products Inc. (Denver, PA 17517). At 120 weeks from the beginning of the study, we performed *in vivo* depletion of CD8 cells in four macaques (93194, 93040, 93043 and 93217) using monoclonal antibody (anti-CD8 cM-T807) as described by Schmitz et al 1999 [27].

#### **SHIV<sub>89,6P</sub> challenge**

To investigate the relative contribution of the second PEP regimen to viral control, we performed SHIV<sub>89,6P</sub> challenge on two PEP-macaques (95020 and M94312) that had similar outcomes of being persistently VAb<sup>±</sup> after the first PMPA PEP, but one (M94312) received second PMPA PEP regimen while the other (95020) did not. As described previously [15] macaque M94312 had previously been given PMPA treatment for 28 days beginning 24 hours after intravenous SIV<sub>mne</sub> inoculation. Macaque 95020 was given PMPA treatment for only 10 days beginning 24 hours after SIV<sub>mne</sub> inoculation. Both macaques had no detectable viremia (plasma SIV RNA or infectious cells in peripheral blood), but they developed weak SIV-antibody response beginning 24 weeks post inoculation detectable as a very weak band for SIVgp120 on immunoblotting (Table 1). Four years later macaque M94312 was given second PMPA PEP regimen of a 5-week PMPA treatment involving a single treatment interruption plus SIV<sub>mne</sub> challenge at week 1 of treatment. Thereafter, this macaque became virus-negative but strongly SIV-antibody positive (VAb<sup>+</sup>) (Fig 1, 2, 3). Macaque 95020 was not given second PMPA PEP and remained persistently VAb<sup>±</sup> (virus-negative and weakly-seropositive). In the present

study, we challenged both macaques intravenously with 10 AID<sub>50</sub> SHIV<sub>89,6P</sub> (6.5 years after first PMPA PEP or 2.5 years after second PMPA PEP). Two naïve macaques (macaques 99111 and 99107) served as infection controls for the virus inoculum. Infection was evaluated during the first 8 weeks after inoculation. The SHIV<sub>89,6P</sub> – was obtained originally from Dr. K.A. Riemann and expanded in macaque PBMC. It is a chimeric virus of SIV/HIV-1 containing *env* gene of HIV-1<sub>89,6P</sub> on SIVmac239 backbone which causes high viral loads and a rapid decline in CD4+ T-cell levels in rhesus macaques [28] and cynomolgus macaques [29]. Plasma SHIV RNA was determined by branched DNA (bDNA) signal amplification assay for SIV, lymphocyte subsets by FACScan flow cytometry (Becton Dickinson, San Jose, CA) for specific CD4+, CD8+, CD3+ and CD20+ lymphocyte subsets. SHIV-antibody response was quantified by limiting dilution assay using a commercial HIV-2 EIA (enzyme immunoassay) kit (Sanofi-Pasteur, Redmond, WA) as described previously [29,41].

#### **Clinical observations**

All macaques were observed daily for general physical condition including appetite, stool consistency, and demeanor. At predetermined time points during the 144 weeks of study, the animals were anesthetized with ketamine for thorough physical examination including body weight and temperature. Blood was drawn for complete blood count, serum chemistry, virology, and lymphocyte subset analyses. Data from clinical assessments was used to monitor the course of SIV infection and clinical disease including drug toxicity.

#### **Laboratory assays**

Laboratory determinations included plasma viral RNA, titers SIV-antibodies and CD4+ and CD8+ T cell counts. Quantitative assays for viral RNA in plasma were performed at Bayer Diagnostics (Berkeley, CA) using a branched DNA (bDNA) signal amplification assay for SIV. This bDNA assay has a lower-limit of detection of 125 RNA copies/ml [39]. Titers of SIV antibodies were determined by end-point dilution of plasma using HIV-2 EIA kit (Sanofi-Pasteur, Redmond, WA). Lymphocyte subsets in EDTA-blood were determined by FACscan using mouse anti-human monoclonal antibodies that react with macaque lymphocytes to determine the absolute numbers of CD4+ and CD8+ T cells and the CD4:CD8 cell ratio was calculated [41].

#### **Competing interests**

The author(s) declare that they have no competing interests.

#### **Authors' contributions**

PE carried out the experiments, performed data analysis and wrote the initial drafts of the manuscript, YJ helped

with laboratory experiments and data interpretation, MA helped with experimental design and data interpretation, BT helped with laboratory and animal experiments and data analysis, GB assisted with animal experiments. CCT was responsible for the overall experimental design, data interpretation and implementation of the project.

## Acknowledgements

The authors thank R. Black and K. Gupta for helpful discussion and critical review of this manuscript, and Kathy. E. Follis, Thomas.W. Beck, Ann Schmidt and Leon Flanary for assistance in animal experiments. We also thank K.A. Reimann together with J. Ghraieb for providing the anti-CD8 mAb cM-T807. This work was partially supported by NIH-NIAID contracts AI-65311 and AI-15450 and NIH grant RR-00166.

## References

1. WHO/UNAIDS: **Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond.** 2006.
2. Patella Fj Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, and HIV Outpatient Study Investigators: **Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study.** *J Acquir Immune Defic Syndr* 2006, **43**:27-34.
3. Richman DD: **HIV Chemotherapy.** *Nature* 2001, **410**:995-1001.
4. UNAIDS/WHO: **AIDS Epidemic Update: Special Report on HIV Prevention.** 2005.
5. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, International PACTG 316 Team: **Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.** *JAMA* 2002, **288**:189-198.
6. Mofenson LM, Centers for Disease Control and Prevention, US Public Health Service Task Force: **U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.** *MMWR Recomm Rep* 2002, **51(RR-18)**:1-38.
7. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, Heptonstall J, Ippolito G, Lot F, McKibben PS, Bell DM: **A case-control study of HIV seroconversion in health care workers after percutaneous exposure. US Centers for Disease Control and Prevention Needlestick Surveillance Group.** *N Engl J Med* 1997, **337**:1485-1490.
8. **Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for post exposure prophylaxis.** *MMWR Recomm Rep* 2001, **50(RR-11)**:1-52.
9. Pozniak A: **Post-exposure prophylaxis for sexual exposure to HIV.** *Curr Opin Infect Dis* 2004, **17**:39-40.
10. Wiebe ER, Comay SE, McGregor M, Ducceschi S: **Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service.** *CMAJ* 2000, **162**:641-645.
11. Bassett IV, Freeberg KA, Walensky RP: **Two drugs or three? Balancing efficacy, toxicity and resistance in post exposure prophylaxis for occupational exposure to HIV.** *Clin Infect Dis* 2004, **39**:395-401.
12. Gayle HD: **Expanding access to HIV prevention.** *AIDS Res Ther* 2006, **3**:2. doi:10.1186/1742-6405-3-2
13. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD: **Immune control of HIV-1 after early treatment of acute infection.** *Nature* 2000, **407**:523-526.
14. Komarova NL, Barnes E, Klenerman P, Wodarz D: **Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy and success.** *Proc Natl Acad Sci USA* 2003, **100**:1855-1860.
15. Tsai CC, Emau P, Follis KE, Beck WT, Benveniste RE, Bischofberger N, Lifson JD, Morton WR: **Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVme infection depends critically on the timing of initiation and duration of treatment.** *J Virol* 1998, **72**:4265-4273.
16. Tsai CC, Follis KE, Sabo A, Beck WT, Grant RF, Bischofberger N, Benveniste RE, Black R: **Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)Adenine.** *Science* 1995, **270**:1197-1199.
17. Tsai CC, Emau P, Sun JC, Follis KE, Beck WT, Tran CA, Bischofberger N, Morton WR: **Post-exposure chemoprophylaxis (PECP) against infection of macaques as a model for protection from HIV infection.** *J Med Primatol* 2000, **29**:248-258.
18. Lifson JD, Rossio JL, Piatak M Jr, Parks T, Li L, Kiser R, Coalter V, Fisher B, Flynn BM, Czajak S, Hirsch VM, Reimann KA, Schmidt J, Ghraieb J, Bischofberger N, Nowak MA, Desrosiers RC, Wodarz D: **Role of CD8+ lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.** *J Virol* 2001, **75**:10187-10199.
19. Kumar A, Buch S, Foresman L, Bischofberger N, Lifson JD, Narayan O: **Development of virus-specific immune responses in SHIV<sub>KU</sub>-infected macaques treated with PMPA.** *Virology* 2001, **279**:97-108.
20. Rosenwirth B, ten Haft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, Bischofberger N, Heeney JL, Uberla K: **Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.** *J Virol* 2000, **74**:1704-1711.
21. Spring M, Stahl-Hennig C, Stolte N, Bischofberger N, Heeney J, ten Haaf P, Tenner-Racz K, Racz P, Lorenzen D, Hunsmann G, Dittmer U: **Enhanced cellular immune responses and reduced CD8 lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.** *Virology* 2001, **279**:221-232.
22. Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J: **Control of SIV rebound through structured treatment interruptions during early infection.** *Science* 2000, **290**:1591-1593.
23. Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, Page A, Wang C, Adany I, Buch S, Bischofberger N, Narayan O: **Lasting effects of transient postinoculation PMPA [9-R-(2-phosphonomethoxypropyl)adenine] treatment on SHIV<sub>(KU2)</sub> infection of rhesus macaques.** *Virology* 2000, **277**:306-315.
24. Van Rompay KK, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N: **CD8+ -cell-mediated suppression of virulent simian immunodeficiency virus during PMPA treatment.** *J Virol* 2004, **78**:5324-5337.
25. Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldridge RL, vanLunzen J, Stellbrink HJ, Walker BD, Luster AD: **HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication.** *Lancet* 2004, **363**:863-866.
26. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A: **Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropylloxymethylcarbonyl)PMPA.** *Antimicrob Agents Chemother* 1998, **42**:612-617.
27. Schmitz JE, Kuroda MJ, SSantra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallan BJ, Ghraieb J, Forman MA, Montiferi DC, Rieber EP, Letvin NL, Reimann KA: **Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.** *Science* 1999, **283**:857-860.
28. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL: **A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type I isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.** *J Virol* 1996, **70**:6922-6928.
29. Tsai CC, Emau P, Jiang Y, Baoping T, Morton W, Gustafson KR, Boyd M: **Cyanovirin-N Gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques.** *AIDS Res Hum Retro* 2003, **19**:535-541.
30. Anita R, Pilyugin SS, Ahmed R: **Models of immune memory: On the role of cross-reactive stimulation, competition, and homeostasis in maintaining immune memory.** *Proc Natl Acad Sci USA* 1998, **95**:14926-14931.

31. Zidek Z, Frankova D, Holy A: **Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.** *Antimicrob Agents Chemother* 2001, **45**:3381-3386.
32. Zidek Z, Frankova D, Holy A: **Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli.** *Int J Immunopharmacol* 2000, **22**:1121-1129.
33. Tsai CC, Follis KE, Sabo A, Grant RF, Bartz C, Nolte RE, Benveniste RE, Bischofberger N: **Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)-adenine against simian immunodeficiency virus infection in macaques.** *J Infect Dis* 1994, **169**:260-266.
34. Tsai C-C, Follis KE, Grant R, Sabo A, Nolte R, Bartz C, Bischofberger N, Benvensite R: **Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques.** *J Med Primatol* 1994, **23**:175-183.
35. Le Grand R, Vaslin B, Largero L: **Post exposure prophylaxis with HAART could not protect macaques from inoculation with SIV/HIV chimera.** *AIDS* 2000, **14**:1846-1866.
36. Mackay GA, Liu Z, Singh DK, Smith MS, Mukherjee S, Sheffer D, Fjia D, Adany I, Sun KH, Dhillon S, Zhuge W, Narayan O: **Protection against late onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus.** *J Immunol* 2004, **173**:4100-4107.
37. Lifson JD, Piatak M Jr, Cline AN, Rossio JL, Purcell J, Pandrea I, Bischofberger N, Blanchard J, Veazey RS: **Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissue in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.** *J Med Primatol* 2003, **32**:201-210.
38. Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ: **Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques.** *AIDS Res Hum Retroviruses* 1997, **13**:707-12.
39. Temin HM, Bolognesi DP: **Where has HIV been hiding?** *Nature* 1993, **362**:292-293.
40. Anaworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne D, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group, Swiss HIV Cohort Study: **CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.** *Lancet* 2006, **368**:459-465.
41. Tsai CC, Emau P, Jiang YH, Shattock R, Agy MB, Schmidt A, Morton WR, Gustafson KR, Boyd MR: **Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models.** *AIDS Res Hum Retroviruses* 2004, **20**:11-18.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

